Evaluation of calcium as an insulin secretagogue in patients with insulinoma

L. M. Brunt, W. G. Dilley, J. R. Farndon

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


CALCIUM ION (Ca++) has been administered as an insulin (IN) secretagogue in doses ranging from 4 to 5 mg/kg/hr over two to five hours in patients with insulinoma (1-4). Some reports (1,2) have indicated a significant increase in plasma IN during the CA++ infusion, while others (3,4) have demonstrated no change. We have previously observed, in patients with medullary thyroid carcinoma, that plasma calcitonin levels increased to higher peak levels more quickly following a rapid calcium infusion (RCI) than following a long calcium infusion (LCI). In the present study, fasting and stimulated plasma IN levels were compared in normal controls and in patients with insulinoma administered these two tests.

Original languageEnglish
Pages (from-to)49-52
Number of pages4
JournalSurgical Forum
VolumeVOL. 35
StatePublished - Jan 1 1984


Dive into the research topics of 'Evaluation of calcium as an insulin secretagogue in patients with insulinoma'. Together they form a unique fingerprint.

Cite this